Cargando…
Correction: Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5(+) colorectal cancer
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683607/ https://www.ncbi.nlm.nih.gov/pubmed/33230188 http://dx.doi.org/10.1038/s41419-020-03208-z |
| _version_ | 1783612917337292800 |
|---|---|
| author | Feng, Haoran Liu, Kun Shen, Xiaonan Liang, Juyong Wang, Changgang Qiu, Weihua Cheng, Xi Zhao, Ren |
| author_facet | Feng, Haoran Liu, Kun Shen, Xiaonan Liang, Juyong Wang, Changgang Qiu, Weihua Cheng, Xi Zhao, Ren |
| author_sort | Feng, Haoran |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7683607 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-76836072020-12-03 Correction: Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5(+) colorectal cancer Feng, Haoran Liu, Kun Shen, Xiaonan Liang, Juyong Wang, Changgang Qiu, Weihua Cheng, Xi Zhao, Ren Cell Death Dis Correction Nature Publishing Group UK 2020-11-23 /pmc/articles/PMC7683607/ /pubmed/33230188 http://dx.doi.org/10.1038/s41419-020-03208-z Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Correction Feng, Haoran Liu, Kun Shen, Xiaonan Liang, Juyong Wang, Changgang Qiu, Weihua Cheng, Xi Zhao, Ren Correction: Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5(+) colorectal cancer |
| title | Correction: Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5(+) colorectal cancer |
| title_full | Correction: Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5(+) colorectal cancer |
| title_fullStr | Correction: Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5(+) colorectal cancer |
| title_full_unstemmed | Correction: Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5(+) colorectal cancer |
| title_short | Correction: Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5(+) colorectal cancer |
| title_sort | correction: targeting tumor cell-derived ccl2 as a strategy to overcome bevacizumab resistance in etv5(+) colorectal cancer |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683607/ https://www.ncbi.nlm.nih.gov/pubmed/33230188 http://dx.doi.org/10.1038/s41419-020-03208-z |
| work_keys_str_mv | AT fenghaoran correctiontargetingtumorcellderivedccl2asastrategytoovercomebevacizumabresistanceinetv5colorectalcancer AT liukun correctiontargetingtumorcellderivedccl2asastrategytoovercomebevacizumabresistanceinetv5colorectalcancer AT shenxiaonan correctiontargetingtumorcellderivedccl2asastrategytoovercomebevacizumabresistanceinetv5colorectalcancer AT liangjuyong correctiontargetingtumorcellderivedccl2asastrategytoovercomebevacizumabresistanceinetv5colorectalcancer AT wangchanggang correctiontargetingtumorcellderivedccl2asastrategytoovercomebevacizumabresistanceinetv5colorectalcancer AT qiuweihua correctiontargetingtumorcellderivedccl2asastrategytoovercomebevacizumabresistanceinetv5colorectalcancer AT chengxi correctiontargetingtumorcellderivedccl2asastrategytoovercomebevacizumabresistanceinetv5colorectalcancer AT zhaoren correctiontargetingtumorcellderivedccl2asastrategytoovercomebevacizumabresistanceinetv5colorectalcancer |